Cohort Study | Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels.

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels – JAMA Oncology

Author Interview: High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade – JAMA

Commentaries:

Tumor mutational burden ‘valuable biomarker’ for ICI response in NSCLC – medwire News

Tumor Mutational Burden Associated With Responses, Immune Cell Infiltration in NSCLC – Cancer Network

Commentary on Twitter

Very high levels of tumor mutational burden (TMB) are associated with benefit from #immunotherapy in NSCLC across PD-L1 expression levels and increased CD8+ T cells infiltration. https://t.co/qbq00ZzjFO #LCSM

— JAMA Oncology (@JAMAOnc) June 22, 2022